Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Genentech
Pulmozyme
Другие языки:

    Pulmozyme

    Подписчиков: 0, рейтинг: 0
    Dornase alfa
    Clinical data
    Trade names Pulmozyme
    AHFS/Drugs.com Monograph
    MedlinePlus a694002
    License data
    Pregnancy
    category
    • AU: B1
    Routes of
    administration    		 Inhalation
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
    • CA: ℞-only / Schedule D
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG
    CompTox Dashboard (EPA)
    ECHA InfoCard 100.029.685
    Chemical and physical data
    Formula C1321H1999N339O396S9
    Molar mass 29254.04 g·mol−1
     ☒NcheckY (what is this?)  (verify)

    Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis. It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. It is produced in Chinese hamster ovary cells.

    Medical uses

    Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.

    Society and culture

    Legal status

    Dornase alfa is an orphan drug.

    Research

    Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.


    Новое сообщение